Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 97, Issue 2, Pages 192-200
Publisher
Wiley
Online
2015-11-26
DOI
10.1111/ejh.12707
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options
- (2014) Brady L. Stein et al. ANNALS OF HEMATOLOGY
- How I treat polycythemia vera
- (2014) A. M. Vannucchi BLOOD
- Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
- (2014) Emmanuel Pourcelot et al. EXPERIMENTAL HEMATOLOGY
- Novel and emerging therapies for the treatment of polycythemia vera
- (2014) Srdan Verstovsek et al. Expert Review of Hematology
- Quality of Life in MPN Comes of Age as a Therapeutic Target
- (2014) Robyn M. Scherber et al. Current Hematologic Malignancy Reports
- Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
- (2013) Fabian P. Siegel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management
- (2013) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
- (2013) G. Barosi et al. BLOOD
- Myeloproliferative neoplasms and thrombosis
- (2013) T. Barbui et al. BLOOD
- Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms
- (2013) Johanna Abelsson et al. LEUKEMIA & LYMPHOMA
- Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
- (2013) Ruben A. Mesa et al. LEUKEMIA RESEARCH
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
- (2011) R. Scherber et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms
- (2011) Peter Johansson et al. LEUKEMIA & LYMPHOMA
- Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
- (2011) Alfonso Quintás-Cardama et al. NATURE REVIEWS DRUG DISCOVERY
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
- (2010) T. Barbui et al. HAEMATOLOGICA
- A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
- (2010) F Passamonti et al. LEUKEMIA
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
- (2009) Giovanni Barosi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
- (2007) R. Tiedt et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now